Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase

Jung‐Hyun Park(National Cancer Institute), Tae‐You Kim(Seoul National University of Science and Technology), Keunwook Lee(Hallym University), Ju‐Hee Lee(Dongguk University), Yeonjoo Jung(Korea University of Science and Technology), Dae‐Kee Kim, Yung‐Jue Bang(Seoul National University), Hyun-Soon Jong, Sang Gyun Kim(Seoul National University Hospital)

Journal of Molecular Medicine

September 12, 2007

10.1007/s00109-007-0260-8

Cited by 52

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer

|New England Journal of Medicine|2014|2k

Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein

|Nature Cell Biology|2000|1.6k

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

|The Lancet|2018|1.3k

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

|The Lancet Oncology|2012|1.3k